Mirum Pharmaceuticals, Inc. Restricted Cash and Cash Equivalents
Mirum Pharmaceuticals, Inc. (MIRM) had Restricted Cash and Cash Equivalents of $1.73 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-08-05
- 2026-06-30: Restricted Cash and Cash Equivalents $1.73M.
- 2026-03-31: Restricted Cash and Cash Equivalents $1.73M.
- 2025-12-31: Restricted Cash and Cash Equivalents $1.48M.
- 2025-09-30: Restricted Cash and Cash Equivalents $480.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $1.73M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.73M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $1.48M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $480.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $480.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $425.00K 10-Q · filed 2025-05-07 |
| 2024-12-31 | $425.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | $425.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $250.00K 10-Q · filed 2024-08-07 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-26 |
| 2023-03-31 | $100.00M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $100.00M 10-K · filed 2024-03-15 |
| 2022-09-30 | $100.00M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $100.00M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $100.00M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $100.00M 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |